BioPharma Credit’s 2025: higher income, healthy dividends, and a bigger cash war chest
BioPharma Credit PLC (BPCR) has posted a solid set of final results for 2025. Net income per share rose to 11.40 cents (2024: 9.99 cents) and the board maintained its long record of quarterly payouts, delivering total dividends related to 2025 of 9.95 cents per share, all covered by profits.
Repayments accelerated, cash piled up ready to redeploy, and the discount to NAV narrowed. There is plenty to like here if you want income exposure to life sciences through secured lending rather than equity risk.
Key numbers investors care about
| Metric | 2025 |
|---|---|
| Net income (after finance costs, before tax) | $129.9 million |
| Net income per share | 11.40 cents |
| NAV per share (31 Dec) | $1.0192 |
| Share price (31 Dec) | $0.9160 |
| Discount to NAV (31 Dec) | 10.1% (2024: 11.3%) |
| Dividend related to 2025 | 9.95 cents per share |
| Dividend yield (company figure) | 10.9% |
| Share buybacks in 2025 | 56,828,879 shares at 86.9 cents; $50.3 million |
| Total net assets | $1,150.9 million |
| Cash and cash equivalents | $422.3 million (36.7% of NAV) |
| Investments made in 2025 | $301.3 million |
| Repayments received in 2025 | $616.6 million |
| Ordinary shares in issue (with voting rights) | 1,129.2 million |
Income engine humming: what drove the result
The core engine is performing. BPCR invested $301.3 million in 2025, spread across senior secured loans (Evolus, Paratek, Precigen, Valneva), senior unsecured convertible notes (Alphatec, Celcuity, Cogent, CytoKinetics) and senior unsecured notes (Harrow). On the other side of the ledger, repayments picked up to $616.6 million (2024: $463.1 million), which both validates credit underwriting and frees capital for new deals.
Realised returns on several positions were attractive: Collegium 2024 delivered a 12.1% gross IRR, BioCryst 15.3%, OptiNose 15.5%. The team also booked gains on selective sales of convertible notes, including Celcuity and Alphatec. Total portfolio income came in at $157.8 million in 2025.
Portfolio snapshot: diversified, but currently cash-heavy
At 31 December 2025 the book was diversified across approved-product lenders, with a notable cash balance following a large Collegium repayment in December.
- Top exposures by fair value: Insmed $217.3 million (18.9%), Novocure $98.3 million (8.5%), Evolus $62.1 million (5.4%).
- Other meaningful positions: UroGen $49.8 million (4.3%), Geron $49.0 million (4.3%), Precigen $48.9 million (4.2%), Tarsus $36.8 million (3.2%), Harrow $36.5 million (3.2%).
- Cash: $422.3 million (36.7% of NAV) ready to deploy.
Concentration is reasonable for a specialist lender, though Insmed at 18.9% is the single largest position to watch. The large cash balance is a short-term drag on income but gives meaningful dry powder for 2026 opportunities.
Discount control and dividends: shareholder-friendly moves
BPCR’s Discount Control Mechanism (DCM) – a board policy to buy back shares when the discount stays wide – was triggered in 2025. The company repurchased 56.8 million shares for $50.3 million at an average 86.9 cents. Buybacks at a discount are typically NAV-accretive and supportive for the share price.
Dividends remained a highlight. Three quarterly payments referencing 2025 totalled 6.75 cents; after the year-end, a further 3.20 cents (1.75 cents ordinary + 1.45 cents special) relating to Q4 2025 was paid on 20 March 2026. The company has paid at least 1.75 cents every quarter since 30 June 2018.
By 20 March 2026, the shares were at 94.00 cents, a 6% discount to NAV, narrower than year-end’s 10.1%.
Early 2026 updates: redeployment gathering pace
- UroGen upsized and extended: a new senior term loan now maturing in 2031 at a fixed 8.25% with additional and exit considerations. The company invested an extra $50 million at signing.
- Zenas BioPharma: a new senior secured loan commitment of up to $125 million across five tranches, at 3‑month SOFR + 5.75% (3.25% floor) plus one-time considerations per tranche.
- Paratek: following its combination with Radius Health, BPCR and the private fund each funded $50 million in new debt that replaced the prior Paratek facility. Terms are described as generally comparable with other BPCR loans.
- CytoKinetics notes: 18 million of the 1.75% 2031 convertible notes were sold at an average $1.29, generating a $5.2 million gain.
Unfunded commitments stood at $316.7 million at year-end across Evolus, Geron, Novocure, Precigen, Paratek, UroGen and Zenas, rising to $366.7 million as of 23 March 2026. That, plus the cash balance, indicates a healthy pipeline and capacity to earn.
Why it matters: my take
Positives:
- Income momentum: higher net income per share and fully covered dividends are exactly what income-focused holders want.
- Proactive discount control: meaningful buybacks at a mid‑teens discount for much of the year are shareholder-friendly and accretive.
- Capital recycling: repayments of $616.6 million demonstrate counterparties’ access to capital and support the manager’s strategy of redeploying into fresh, higher‑spread paper.
- Pipeline and post‑period activity: early 2026 deal flow (UroGen, Zenas, Paratek) shows the cash is being put back to work, with attractive coupons and fees.
Watch‑outs:
- Cash drag: 36.7% of NAV in cash at year‑end suppresses near‑term income until fully invested, though early 2026 steps are addressing this.
- Single‑name exposure: Insmed at 18.9% is sizeable. Performance there matters for NAV stability.
- Healthcare pricing risk: several borrowers sell in markets with US government reimbursement exposure. No 2025 regulatory changes were flagged as material, but it remains a standing risk.
Rates, structures and risk: how the book is positioned
BPCR mixes fixed and floating exposure. A number of loans reference SOFR with floors between 2.25% and 3.75%. At 31 December 2025, 1‑ and 3‑month SOFR (3.69% and 3
